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Abstract
Introduction:  Despite  diagnostic  and  therapeutic  advances,  infective  endocarditis  (IE)  remains
a challenging  and  potentially  lethal  disease.  The  prognosis  of  IE  remains  poor;  in  the  last
30 years,  its  incidence  and  mortality  have  only  been  marginally  reduced.  Early  identiﬁcation  of
high-risk patients  can  change  the  course  of  the  disease  and  improve  outcomes.
Objectives  and  methods: To  describe  and  investigate  predictors  of  mortality  during  hospital
stay and  in  the  six  months  after  discharge  in  a  cohort  of  left-sided  IE  patients  in  two  tertiary
centers. All  patients  diagnosed  with  IE  (ICD9  code  133)  were  registered  in  a  uniform  database.
Results: One  hundred  and  forty-seven  consecutive  case  patients  with  left-sided  IE  were  included
in this  study.  Thirty-ﬁve  patients  (23.8%)  died  during  hospital  stay.  The  variables  signiﬁcantly
associated  with  increased  mortality  in  univariate  analysis  were  Charlson  index  ≥5,  use  of  immu-
nosuppressants,  sepsis  (severe  sepsis  and/or  septic  shock),  cardiogenic  shock  and  inappropriate
use of  antibiotic  therapy.  Conversely,  surgical  therapy  and  hospital  length  of  stay  ≥30  days  were
signiﬁcantly  associated  with  lower  mortality.  In  multivariate  analysis  the  most  important  pre-
dictors of  in-hospital  mortality  were  sepsis  (severe  and/or  shock),  use  of  immunosuppressants
and inappropriate  use  of  antibiotic  therapy.  There  was  a  signiﬁcant  relation  between  the  use
of immunosuppressants  and  the  occurrence  of  sepsis.  The  presence  of  signiﬁcant  valve  disease
after IE  signiﬁcantly  increased  the  risk  of  heart  failure.
Conclusions:  Our  results  may  help  to  identify  IE  patients  at  increased  risk  for  in-hospital  mor-
loaded from http://http://www.elsevier.pt, day 13/11/2013. This copy is for personal use. Any transmission of this document by any media or format is strictly prohibited.tality and  medium-term  disability.  These  ﬁndings  can  help  to  identify  candidates  for  earlier  and
more aggressive  management.
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Endocardite  infecciosa  esquerda:  análise  de  prognóstico  e  preditores  de  mortalidade
Resumo
Introduc¸ão:  Apesar  dos  avanc¸os  no  diagnóstico  e  terapêutica  da  endocardite  infecciosa,  esta
patologia  mantém-se  desaﬁante  e  potencialmente  fatal.  O  prognóstico  desta  doenc¸a  mantevese
praticamente  inalterado  nos  últimos  30  anos.  A  identiﬁcac¸ão  precoce  dos  doentes  de  alto  risco
pode alterar  o  curso  da  doenc¸a  e  melhorar  o  prognóstico.
Objetivos  e  métodos: Descrever  e  investigar  os  preditores  de  mortalidade  durante  o  interna-
mento e  nos  seis  meses  após  a  alta  dos  doentes  com  diagnóstico  de  endocardite  infecciosa
esquerda  (código  ICD9:  133).
Resultados:  Foram  incluídos  147  doentes  com  endocardite  infecciosa  esquerda.  Trinta  e  cinco
doentes (23,8%)  morreram  durante  o  internamento.  Registou-se  um  aumento  signiﬁcativo  da
mortalidade  na  análise  univariada  com:  Charlson  index  ≥  5,  uso  de  imunossupressores,  sépsis
(sépsis grave  e/ou  choque  sético),  choque  cardiogénico  e  uso  inapropriado  de  antibioterapia.
Contudo,  a  realizac¸ão  de  cirurgia  cardíaca  e  tempo  de  internamento  ≥  30  dias  associaramse
signiﬁcativamente  com  taxas  de  mortalidade  mais  baixas.  Os  preditores  mais  relevantes
de mortalidade  intra-hospitalar  na  análise  multivariada  foram:  sépsis  (grave  e/ou  choque),
uso de  imunossupressores  e  uso  inapropriado  de  antibioterapia.  Veriﬁcou-se  uma  interac¸ão  sig-
niﬁcativa entre  o  uso  de  imunossupressores  e  a  ocorrência  de  sépsis.  A  presenc¸a  de  patologia
valvular após  resoluc¸ão  do  quadro  infeccioso  aumentou  o  risco  de  insuﬁciência  cardíaca.
Conclusões:  Os  nossos  resultados  podem  ajudar  a  identiﬁcar  quais  os  doentes  com  maior  risco
de mortalidade  intra-hospitalar  e  de  complicac¸ões  a  médio  prazo,  assim  como  ajudar  a  triar  os
candidatos  que  devem  ser  sujeitos  a  uma  monitorizac¸ão  mais  apertada.
© 2012  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.  Todos  os
direitos reservados.
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espite  diagnostic  and  therapeutic  advances,  infective
ndocarditis  (IE)  remains  a  challenging  and  potentially
ethal  disease1 with  a  dismal  prognosis.  In  the  last
0  years  the  incidence  and  mortality  of  IE  have  only  been
arginally  reduced.2 Most  series  report  in-hospital  mor-
ality  between  9.6  and  26%3--7 and  long-term  (more  than
ix  months)  mortality  between  20  and  37.1%.7--9 Only  a
imited  number  of  studies  have  focused  on  medium-term
utcomes.10
Heterogeneity  in  clinical  presentation,  the  presence  of
tructural  heart  disease,  the  different  types  of  microor-
anism  involved,  the  development  of  complications,  and
atient  characteristics,  all  require  a  multidisciplinary  team
o  be  involved  in  the  treatment  of  IE.1,11 Many  stud-
es  suggest  that  early  identiﬁcation  of  high-risk  patients
an  change  the  course  of  the  disease  and  improve
utcomes.12
Prognosis  is  inﬂuenced  by  four  types  of  factors:  patient
haracteristics,  associated  complications,  microbial  eti-
logy,  and  echocardiographic  ﬁndings.3,13 Patients  with
eart  failure  (HF),  perivalvular  complications,  and/or
ethicillin-resistant  Staphylococcus  aureus  (MRSA)  infec-
ions  usually  have  higher  mortality  and  often  need  surgery
n  the  active  disease  phase.13,14 Several  studies  have
dentiﬁed  different  independent  prognostic  factors  asso-
iated  with  higher  mortality,  such  as  higher  number
f  comorbidities,  advanced  age,  renal  insufﬁciency,  sep-
ic  shock,  insulin-dependent  diabetes,  heart  failure  with
educed  ejection  fraction,  prosthetic  valve  IE,  and  cerebral
mbolism.3,5,7,15,16
t
i
f
cbjectives
o  determine  the  characteristics  of  our  population  with  left-
ided  IE  and  to  investigate  factors  associated  with  higher
ortality  during  hospital  stay  and  in  the  six  months  after
ischarge  in  a  two-center  cohort  of  left-sided  IE  patients.
his  analysis  is  intended  to  identify  clinical  procedures  that
ould  be  improved  to  minimize  mortality  associated  with
eft-sided  IE.
ethods
tudy  population
ll  patients  diagnosed  with  IE  (ICD9  code  133)  in  two
ertiary  hospitals  in  Porto,  Portugal,  were  registered  in  a  uni-
orm  database  based  on  information  from  medical  records
etween  January  2000  and  June  2011.  The  study  included
ases  from  both  community  and  referral  hospitals.
riteria  and  deﬁnitions
eft-sided  IE  was  deﬁned  according  to  the  modiﬁed  Duke
riteria17 for  deﬁnite  or  possible  IE.
For  each  case,  data  were  collected  regarding  age,  gen-
er,  valvular  involvement,  comorbidities,  echocardiographic
ndings,  microbiologic  agents,  associated  complications,
reatment  (including  surgery),  and  outcome  (in-hospital  and
n  the  six  months  after  discharge).  The  European  System
or  Cardiac  Operative  Risk  Evaluation  (EuroSCORE)  surgi-
al  risk  score18 was  determined  in  all  patients.  In  patients
Left-sided  infective  endocarditis  779
Table  1  Microbiologic  etiology  by  mode  of  acquisition.
Agent  Community-acquired  Health-care  associated  Nosocomial  Total
Methicillin-sensitive  Staphylococcus  aureus  28  (23.1)  2  (1.7)  6  (5)  36  (29.8)
Methicillin-resistant  Staphylococcus  aureus  5  (4.1)  5  (4.1)  11  (9.1)  21  (17.4)
Streptococcus  viridans  group  17  (14)  3  (2.5)  1  (0.8)  21  (17.4)
Beta-hemolytic  streptococci  groups  A,  B,  C  and  G  8  (6.6)  4  (3.3)  0  12  (9.9)
Enterococcus  spp.  7  (5.9)  2  (1.7)  2  (1.7)  11  (9.1)
Streptococcus  bovis  7  (5.9)  1  (0.8)  0  8  (6.6)
HACEK group  2  (1.7)  1  (0.8)  2  (1.7)  5  (4.1)
Others 4  (3.3)  1  (0.8)  2  (1.7)  7  (5.9)
Total 78  (64.5) 19  (15.7) 24  (19.9) 121  (100)
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undergoing  surgery,  the  Society  of  Thoracic  Surgeons  (STS)
surgical  risk  score19 was  also  used.
Patients  with  no  signs  of  infection  and  negative  blood
cultures  after  a  complete  course  of  antibiotic  therapy
were  considered  cured.  Relapse  was  deﬁned  as  a  new  IE
episode  caused  by  the  same  agent  within  six  months.  Rein-
fection  was  deﬁned  as  a  new  IE  episode  caused  by  a  different
agent.
Immunosuppression  was  considered  to  be  present  when
patients  had  been  taking  immunosuppressants  or  ≥15  mg
of  prednisolone  or  equivalent  for  more  than  three  months
and/or  had  CD4  counts  of  <350  cells/mm3 when  infected
with  human  immunodeﬁciency  virus.
Appropriacy  of  antibiotic  therapy  was  deﬁned  according
to  the  latest  guidelines.12
The  primary  outcome  was  overall  all-cause  in-hospital
mortality  and  death  from  cardiac  cause  within  six  months
of  discharge.
The  study  was  approved  by  the  local  ethics  committee.
Statistical  analysis
Comparison  between  groups  was  performed  with  parametric
or  non-parametric  tests,  as  appropriate.  Continuous  varia-
bles  are  expressed  as  mean  ±  standard  deviation  (SD)  or
median  (inter-quartile  range,  IQR).  Categorical  variables  are
expressed  in  absolute  numbers  and  proportions.
The  association  between  variables  and  the  primary  out-
come  was  ﬁrst  tested  by  univariate  analysis.  A  signiﬁcant
association  was  deﬁned  by  a  p  value  ≤0.05.  Variables  with
signiﬁcant  association  were  tested  by  stepwise  multivariate
analysis.  Predictors  of  outcome  were  identiﬁed  by  logistic
regression  analysis.  The  statistical  analysis  was  performed
using  SPSS  software  version  19,  Chicago,  IL,  USA.
Results
One  hundred  and  forty-seven  consecutive  case  patients  with
left-sided  IE  were  included.  The  median  age  was  63  years
(IQR  45-74).  One  hundred  and  ﬁve  (71.4%)  were  male.
One  hundred  and  twenty-nine  (87.8%)  cases  were  consid-
ered  as  deﬁnite  and  18  (12.2%)  as  possible  IE,  according  to
the  modiﬁed  Duke  criteria.
Most  patients  (128,  87.1%)  had  IE  on  native  valves.  Of
the  19  (12.9%)  patients  with  prosthetic  valves,  3  (16%)  were
v
v
vonsidered  early  and  16  (84%)  late  IE.  The  aortic  valve  was
ffected  in  74  (50.3%)  cases,  the  mitral  valve  in  60  (40.8%),
nd  both  valves  in  13  (8.8%)  patients.
Ninety-three  patients  (63.3%)  underwent  both  transtho-
acic  (TTE)  and  transesophageal  (TEE)  echocardiography,
8  (32.7%)  had  TTE  alone,  and  six  (4.1%)  TEE  alone.  Overall,
1  (55.1%)  had  a  valvulopathy  and/or  intervention  possibly
redisposing  for  IE:  31  (21.1%)  had  degenerative  valvular
isease;  20  (13.6%)  had  prosthetic  valves;  12  (8.2%)  had  con-
enital  heart  disease;  12  (8.2%)  had  recently  undergone  an
nvasive  gastrointestinal  intervention;  ﬁve  (3.4%)  had  previ-
us  IE;  and  one  (0.7%)  had  rheumatic  valvular  disease.
The  median  Charlson  index  was  5  (IQR  3-7).  One  hundred
nd  sixteen  (78.9%)  patients  had  signiﬁcant  comorbidities.
f  these,  37  (25.2%)  had  diabetes  (of  whom  15  [10.2%]
ere  taking  insulin  and  22  [15%]  were  taking  oral  antidia-
etic  agents),  27  (18.4%)  were  taking  immunosuppressive
gents,  17  (11.6%)  had  renal  failure  undergoing  dialysis,
5  (10.2%)  had  active  cancer,  15  (10.2%)  were  intravenous
rug  abusers,  12  (8.2%)  had  liver  cirrhosis,  and  11  (7.5%)  had
hronic  obstructive  pulmonary  disease  (COPD).
Fever  and/or  general  symptoms  were  present  for  about
 month  before  admission  (median  27.5  days,  IQR  15-30).
Etiology  was  established  by  isolating  the  causative
gent  from  blood  culture  in  121  (82.3%)  patients.  Ninety-
ight  (66.7%)  of  the  infections  were  community-acquired,
1  (14.3%)  were  health-care  associated,  and  28  (19%)  were
osocomial.  Methicillin-sensitive  Staphylococcus  aureus
MSSA)  was  the  most  frequent  microorganism  isolated,
ollowed  by  methicillin-resistant  Staphylococcus  aureus
MRSA),  Streptococcus  viridans  group,  beta-hemolytic
treptococci  groups  A,  B,  C  and  G  and  Enterococcus  spp.
Table  1).  Antibiotic  therapy  was  considered  appropriate  in
23  (83.7%)  patients.  In  the  24  (16.3%)  patients  in  whom
ntibiotic  therapy  was  considered  inappropriate,  this  was
ue  to  short  duration  of  treatment  in  nine  (6.1%)  patients,
nappropriate  spectrum  in  nine  (6.1%)  patients,  and  inap-
ropriate  duration  and  spectrum  in  four  (2.7%).  Five  (3.4%)
atients  had  infection  relapse  and  another  ﬁve  had  reinfec-
ion.
Seventy-nine  (53.7%)  patients  had  a  single  vege-
ation  smaller  than  20  mm,  16  (10.9%)  had  a  single
egetation  larger  than  20  mm,  and  52  (35.4%)  had  multiple
egetations.
Complications  were  frequent:  54  (36.7%)  had  severe
alvular  regurgitation  (28  [19%]  involving  the  aortic  valve
7 J.P.  Ferreira  et  al.
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Delay  in  diagnosis,  complications,  length  of  hospital  stay,
and  mortality  remain  high  in  IE.1 Although  mortality  lower
than  20%  has  been  reported,23,24 it  usually  ranges  between
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nd  26  [17.7%]  involving  the  mitral  valve),  39  (26.5%)  had
erivalvular  complications  (of  whom  27  [18.4%]  had  an
bscess,  ﬁve  [3.4%]  had  a  ﬁstula,  ﬁve  [3.4%]  had  perforation,
wo  [1.4%]  had  aneurysm,  50  (34%)  had  peripheral  and/or
plenic  embolic  phenomena,  31  (21.1%)  presented  neuro-
ogic  complications  (of  whom  21  [14.3%]  had  septic  emboli,
ix  [4.1%]  had  hemorrhage,  three  [2%]  had  abscess,  and  one
0.7%]  had  meningitis),  22  (15%)  had  septic  shock,  16  (10.9%)
ad  cardiogenic  shock,  and  three  (2%)  had  myocardial  infarc-
ion.
Valvular  surgery  was  performed  in  57  (38.8%)  patients
urgent/emergent  in  47  [31.9%]  patients  and  scheduled  in
0  [6.8%]  cases).  Of  the  patients  undergoing  surgery,  the  aor-
ic  valve  was  replaced  in  28  (19%)  patients,  the  mitral  valve
n  18  (12.2%),  and  both  valves  in  10  (6.8%).  All  the  57  patients
ndergoing  surgery  had  heart  failure  and  valve  dysfunction.
f  these,  40  (70%)  had  severe  valvular  regurgitation  and
4  (42%)  had  perivalvular  complication  with  extension  of  the
nfectious  process.  In  the  patients  who  underwent  surgery,
he  median  STS  score  was  4.5  (IQR  1.4-8.3),  and  the  median
uroSCORE  was  4.4  (IQR  1.6-6.9).  There  were  no  differences
n  EuroSCORE  values  between  patients  who  did  and  who  did
ot  undergo  surgery  (OR  0.99;  95%  conﬁdence  interval  [CI]
.97-1;  p=0.9).  Of  these  57  patients  post-surgery  informa-
ion  was  available  for  54:  14  (25.9%)  had  complications  (four
29%]  pneumonia,  two  [14%]  arrhythmia,  two  [14%]  stroke,
wo  [14%]  death,  two  [14%]  cardiac  tamponade,  one  [7%]
schemic  heart  disease,  and  one  [7%]  valvular  dysfunction);
he  other  40  (74.1%)  had  no  events.
Thirty-ﬁve  patients  (23.8%)  died  during  hospital  stay.
he  main  causes  of  death  were  septic  shock  in  13  (37.1%)
atients,  cardiogenic  shock  in  8  (22.9%),  and  neurologic
omplications  in  a  similar  percentage.
The  variables  signiﬁcantly  associated  with  increased
n-hospital  mortality  in  univariate  analysis  were  Charlson
ndex  ≥5,  EuroSCORE  >6,  use  of  immunosuppressants,  sepsis
severe  and/or  shock),  cardiogenic  shock  and  inappropriate
se  of  antibiotic  therapy.  Conversely,  patients  who  under-
ent  surgery  and  those  with  hospital  stay  ≥30  days  had
igniﬁcantly  lower  mortality  (Table  2).  In  multivariate  anal-
sis  the  most  important  predictors  of  mortality  were  sepsis
severe  and/or  shock)  (odds  ratio  [OR]  10.6;  95%  CI  3.5-
1.7;  p<0.001),  use  of  immunosuppressants  (OR  8.6;  95%
I  2.6-28.8;  p<0.001),  EuroSCORE  >6  (OR  3.5;  95%  CI  1.2-
.7;  p=0.019),  and  inappropriate  use  of  antibiotic  therapy
OR  6.8;  95%  CI  2.0-23.6;  p=0.002).  There  was  a  signiﬁcant
elation  between  the  use  of  immunosuppressants  and  sepsis
p=0.003).
Patients  with  EuroSCORE  >6  had  increased  mortality,  but
his  was  not  statistically  signiﬁcant  (OR  3;  95%  CI  0.6-14.3;
=0.15).  In  our  study  the  EuroSCORE  cut-off  that  maxi-
ized  sensitivity  and  speciﬁcity  for  predicting  mortality  was
 (area  under  the  curve  0.75;  95%  CI  0.65-0.86;  p<0.001)
Figure  1).
The  median  length  of  hospital  stay  was  40  days  (IQR  22.5-
6).
During  the  six  months  after  hospitalization,  another
1  (9.8%)  patients  died,  nine  (81.8%)  due  to  IE  complications
heart  failure  due  to  valvular  dysfunction),  and  two  (18.2%)
ue  to  other  causes  (infectious  complications).  Thirty-eight
atients  developed  heart  failure  (32  [84.2%]  in  New  York
eart  Association  [NYHA]  class  II  and  six  [15.8%]  in  NYHA
F
d1- specificity
Figure  1  Receiver  operator  curve  for  EuroSCORE.
lass  III).  Fifteen  patients  had  valvular  dysfunction  (ﬁve
33.3%]  moderate  aortic  regurgitation,  one  [6.7%]  severe
ortic  regurgitation,  seven  [46.7%]  moderate  mitral  regur-
itation,  and  two  [13.3%]  severe  mitral  regurgitation).  Ten
atients  had  neurologic  sequelae  (six  [60%]  motor  and  four
40%]  other  complications  such  as  epilepsy,  diplopia,  and
phasia).
The  presence  of  valvular  sequelae  after  IE  signiﬁcantly
ncreased  the  risk  of  heart  failure  and  mortality  due  to
ardiac  causes  during  follow-up  (OR  7.4;  95%  CI  2.3-23.5;
=0.001  and  OR  1.6;  95%  CI  1.2-6.3;  p<0.001,  respectively).
ean  survival  was  four  months  (95%  CI  3.3-4.6)  (Figure  2).
iscussion
n  our  study,  we  observed  similar  characteristics  and  out-
omes  for  IE  patients  to  those  described  previously.2,10,12
We  see  in  the  infrequent  use  of  inappropriate  antibi-
tic  therapy  (duration  and/or  spectrum)  an  opportunity  to
20--22Death After Hospitalization
igure  2  Kaplan-Meier  curve  for  survival  (months)  after
ischarge.
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Table  2  Univariate  analysis  of  in-hospital  mortality.
Variable
(reference  variable)
Risk  variable  Deaths
n=35  (%)
OR  95%  CI  p
Gender
(female)
Male  25  (71.4)  1.0  0.4-2.3  0.58
Vegetation
(multiple)
Single <20  mm  20  (57.1)  1.13  0.5-2.6  0.77
Single >20  mm  3  (8.6)  0.8  0.2-3.2  0.72
Acquisition
(health-care associated)
Community  20  (57.1)  1.1  0.3-3.6  0.88
Nosocomial  11  (31.4)  2.8  0.7-10.4  0.14
Age
(≤50 years)
51-74  years  14  (40)  1.14  0.4-2.9  0.83
≥75 years 13  (37.1) 2.86 0.9-7.2  0.07
Charlson score
(≤4)
5-7  18  (51.4) 2.8 1.1-7.0  0.028
≥8 9 (25.7) 5.7 1.8-18.1  0.003
Valve type
(native)
Prosthetic  5  (14.3)  1.17  0.4-3.5  0.78
Agent
(no isolate)
Methicillin-sensitive
Staphylococcus
aureus
8  (22.9)  1.57  0.4-5.9  0.5
Methicillin-resistant
Staphylococcus
aureus
7 (20)  2.75  0.7-11.1  0.16
Streptococcus
viridans group
5  (14.3)  1.7  0.4-7.4  0.47
Others 11  (31.4)  1.9  0.5-6.7  0.3
Perivalvular
complications
(no complications)
Complications
(abscess,  ﬁstula,
perforation)
10  (28.6)  1.15  0.5-2.7  0.75
Chronic dialysis
(yes)
No  4  (11.4)  0.98  0.3-3.2  0.98
Acute renal  failure
(no)
Yes 12  (34.3)  1.8  0.8-4.1  0.16
Duration of  symptoms
before  admission
(≤30  days)
>30  days  4  (11.4)  0.35  0.1-1.1  0.07
Hospital length
of  stay
(≤30  days)
>30  days  16  (45.7)  0.45  0.2-0.9  0.04
Valvular regurgitation
(severe)
Not  severe  24  (68.9)  1.3  0.6-3.1  0.5
Recurrence or
reinfection
(no)
Yes  4  (11.4)  2.3  0.6-8.6  0.22
Diabetes
(no)
Yes 4  (11.4)  1.4  0.6-3.3  0.45
Immunosuppressants
(no)
Yes 13  (37.1)  4.1  1.7-10.0  0.001
Cirrhosis
(no)
Yes 3  (8.6)  1.1  0.3-4.2  0.9
Active cancer
(no)
Yes  5  (14.3)  1.7  0.5-5.4  0.37
Intravenous drug
abuse
(no)
Yes  5  (14.3)  1.7  0.5-5.4  0.37
Dental caries
(no)
Yes  10  (28.6)  1.3  0.5-2.9  0.6
Chronic obstructive
pulmonary  disease
Yes  4  (11.4)  1.9  0.5-7.0  0.32
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Table  2  (Continued)
Variable
(reference  variable)
Risk  variable  Deaths
n=35  (%)
OR  95%  CI  p
Peripheral  embolic
events
(no)
Yes  13  (37.1)  1.2  0.5-2.6  0.66
Neurologic
complications
(septic emboli,
hemorrhage,
abscess,
meningitis)  (no)
Yes 8  (2.9) 1.1  0.5-2.9  0.77
Sepsis
(no)
Overall 28  (80)  6.2  2.5-15.4  <0.001
Severe 15  (42.9)  4.2  1.6-11.2  0.005
Shock 13  (37.1)  14.0  4.4-44.4  <0.001
Cardiogenic shock
(no)
Yes  8  (22.9)  3.9  1.3-11.2  0.013
Surgery
(no)
Yes 8  (22.9)  0.4  0.2-0.9  0.03
Antibiotic therapy
(appropriate)
Inappropriate  11  (31.4)  3.5  1.4-8.7  0.008
EuroSCORE
(≤6)
>6 23  (67.6)  4  1.8-9.1  0.001
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0%  and  30%.4 In  our  study,  in-hospital  mortality  of  23.8%
as  observed,  suggesting  that  our  population  reﬂects  similar
amples  from  registries.
A  Charlson  index  of  more  than  2  has  been  reported
o  be  an  independent  risk  factor  for  mortality  in  previous
tudies.15,25 We  used  the  age-adjusted  index,  assuming  age
o  be  related  to  poor  prognosis.26 In  our  study,  age  ≥75  years
ad  a  trend  towards  higher  mortality.  Signiﬁcantly  higher
ortality  was  found  in  patients  taking  immunosuppressants,
imilar  to  that  reported  in  a  French  study.7
The  EuroSCORE  tool  is  used  for  predicting  in-hospital
ortality  for  cardiac  surgery.27 A  EuroSCORE  >6  is  considered
igh  risk.28 Our  results  are  consistent  with  this  classiﬁcation;
e  also  found  it  useful  for  predicting  overall  mortality  (in
ll  patients).  Based  on  these  ﬁndings  we  recommend  calcu-
ating  the  EuroSCORE  for  any  patient  admitted  for  infective
ndocarditis.
Shorter  (≤30  days)  hospital  stay  was  associated  with
ncreased  mortality  (most  patients  died  in  the  ﬁrst  30  days
f  hospital  stay).
Sepsis  with  dysfunction  of  two  or  more  organs  was  inde-
endently  associated  with  increased  mortality.  Previous
tudies  have  found  an  association  between  septic  shock  and
ncreased  mortality.5,26 This  variable,  particularly  severe
epsis,  helps  to  identify  high-risk  patients  who  can  beneﬁt
rom  early,  protocol-based  aggressive  management.
Unlike  other  studies3 we  did  not  ﬁnd  heart  failure  at
dmission  (NYHA  class  III  or  IV)  to  be  associated  with  worse
rognosis.  This  observation  corroborates  previous  results
ointing  in  the  same  direction.26 However,  mortality  was
igher  when  patients  developed  cardiogenic  shock  during
ospitalization.  One  possible  explanation  for  these  ﬁndings
s  that  development  of  cardiogenic  shock  during  hospital-
zation  is,  in  most  cases,  due  to  severe  valve  dysfunction
a
s
meeding  emergent  surgical  repair.  By  contrast,  heart  failure
t  admission  (due  to  ﬂuid  overload,  arrhythmia,  anemia,
tc.)  can  be  resolved  with  medical  treatment.
The  role  of  surgery  in  the  treatment  of  infective
ndocarditis  is  expanding,  and  current  guidelines  advo-
ate  surgical  management  for  complicated  left-sided  IE.12
arly  surgery  is  also  strongly  indicated  for  patients  with
E  and  congestive  heart  failure.14 Recently,  another  study
ound  that  early  surgery  in  patients  with  IE  and  large
egetations  signiﬁcantly  reduced  death  from  any  cause
nd  speciﬁcally  embolic  events  by  effectively  decreasing
he  risk  of  systemic  embolism.29 Surgery  was  also  found
o  be  a  protective  factor  in  our  study.  This  interest-
ng  ﬁnding  has  been  described  in  previous  observational
tudies.3,15,26 This  is  probably  related  to  the  high  number  of
omplicated  cases  with  severe  valvular  dysfunction  and  car-
iogenic  shock.  However,  these  results  should  be  interpreted
ith  caution  since  this  was  a  retrospective  observational
tudy.
As  expected,  inappropriate  use  of  antibiotic  therapy  was
trongly  associated  with  increased  mortality,  reinforcing
he  need  for  correct  management  of  blood  cultures,  early
nitiation  of  antibiotic  therapy,  and  adjustments  accord-
ng  to  pharmacokinetics,  pharmacodynamics,  microbiologic
ndings,  and  current  recommendations  regarding  length  of
reatment  and  potential  antimicrobial  associations.12
Diabetes,30 prosthetic  valve  IE,31 Staphylococcus  aureus
tiology,32 neurologic  complications,24 large  vegetations,25
nd  perivalvular  extension  of  infection13,24 have  all  been
dentiﬁed  as  risk  factors  for  higher  mortality.  Such  associ-
tions  were  not  found  in  our  study,  possibly  due  to  the  small
ample  size  in  each  setting.
In  our  study,  six-month  mortality  was  9.8%,  similar  to
edium-term  outcomes  described  by  other  authors.10,33
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Not  surprisingly,  the  presence  of  valvulopathy  after  IE  sig-
niﬁcantly  increased  the  risk  of  heart  failure  at  six  months
after  discharge.  No  signiﬁcant  associations  were  found  with
mortality  at  six  months,  possibly  due  to  the  small  number  of
deaths  recorded.
Our  study  has  certain  limitations:  (1)  it  was  a  retrospec-
tive  observational  study:  information  was  limited  to  medical
records,  important  data  may  have  been  incomplete,  and
some  results  may  be  biased  (such  as  the  protective  effect
of  surgery,  since  high  surgical  risk  patients  may  have  been
refused  surgery);  (2)  changes  in  the  clinical  management
of  IE  have  occurred  during  the  study  period;  (3)  some  cases
were  from  referral  centers,  and  so  the  percentage  of  compli-
cated  cases  may  be  overestimated;  (4)  some  patients  were
lost  to  follow-up  or  transferred  to  other  hospitals.
Conclusions
The  development  of  severe  sepsis  is  a  strong  predictor  of  a
dismal  outcome  and  antibiotic  treatment  should  be  started
promptly.  Patients  on  immunosuppressants  also  have  a worse
prognosis.  As  expected,  obtaining  an  early  diagnosis  and
following  the  antibiotic  guidelines  have  a  positive  impact
on  outcome.  The  need  for  surgery  is  mainly  determined  by
heart  failure,  which  should  be  carefully  evaluated.
Our  results  may  help  to  identify  IE  patients  at  increased
risk  for  in-hospital  mortality  and  medium-term  disability.
These  ﬁndings  can  help  to  identify  candidates  for  earlier
and  more  aggressive  management.
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